Lobular Neoplasia disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: LBL001 MIFTS: 54	Lobular Neoplasia Categories: Cancer diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Lobular Neoplasia

MalaCards integrated aliases for Lobular Neoplasia:

Name: Lobular Neoplasia ¹² ¹⁵ ⁷⁰

Lobular Carcinoma in Situ ¹² ³²

Lobular Carcinoma in Situ of Breast ⁷⁰

Non-Infiltrating Lobular Carcinoma ⁷⁰

Lobular Intraepithelial Neoplasia ¹²

Classifications:

MalaCards categories:
Global: Cancer diseases

See all MalaCards categories (disease lists)

ICD10: ³²

Neoplasms

In situ neoplasms

Carcinoma in situ of breast

Lobular carcinoma in situ

External Ids:

Disease Ontology ¹² DOID:3010

NCIt ⁵⁰ C27939

ICD10 ³² D05.0

UMLS ⁷⁰ C0279563 C0334381 C0861352

Sources

Summaries for Lobular Neoplasia

Disease Ontology : ¹² A breast carcinoma in situ that is characterized by abnormal cells are found in the lobules (glands that make milk) of the breast.

MalaCards based summary : Lobular Neoplasia, also known as lobular carcinoma in situ, is related to comedo carcinoma and papillary carcinoma. An important gene associated with Lobular Neoplasia is CDH1 (Cadherin 1), and among its related pathways/superpathways are ERK Signaling and PAK Pathway. The drugs Tamoxifen and Afimoxifene have been mentioned in the context of this disorder. Affiliated tissues include breast, ovary and lung, and related phenotypes are Decreased cell migration and Increased focal adhesion (FA) area, decreased number of small and round FAs, increased peripheral FA formation, increased cell spreading

Wikipedia : ⁷³ Lobular neoplasia can refer... more...

Sources

Related Diseases for Lobular Neoplasia

Diseases related to Lobular Neoplasia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 274)

#	Related Disease	Score	Top Affiliating Genes
1	comedo carcinoma	30.6	PGR ESR1 ERBB2
2	papillary carcinoma	30.1	PGR MUC1 ESR1 ERBB2 CDH1
3	gynecomastia	30.0	PGR ESR2 ESR1 ERBB2
4	small cell carcinoma	30.0	MUC1 ERBB2 BRCA2
5	breast fibroadenoma	30.0	PGR ESR1 ERBB2 CT45A10 BRCA1
6	tubular adenocarcinoma	29.9	PGR MUC1 ESR1 ERBB2 CTNNB1 CDH1
7	hypertrophy of breast	29.9	PGR ESR1 ERBB2 BRCA2 BRCA1
8	bilateral breast cancer	29.7	PGR ESR1 ERBB2 CDH1 BRCA2 BRCA1
9	rhabdomyosarcoma	29.7	ESR1 ERBB2 CTNNB1 BRCA2 BRCA1
10	gastric cancer, hereditary diffuse	29.6	CTNND1 CTNNB1 CTNNA1 CDH1 BRCA2 BRCA1
11	intraductal papilloma	29.5	PGR KRT5 ESR1 ERBB2
12	esophageal cancer	29.5	MUC1 MIR375 ERBB2 CTNNB1 CDH1 BRCA2
13	ductal carcinoma in situ	29.2	PIP PGR MUC1 KRT5 ESR2 ESR1
14	in situ carcinoma	28.7	PIP PGR MUC1 KRT5 ESR1 ERBB2
15	breast disease	28.6	PRLR PGR KRT5 ESR2 ESR1 ERBB2
16	breast carcinoma in situ	28.5	PGR KRT5 ESR1 ERBB2 CTNNB1 CT45A10
17	breast ductal carcinoma	27.8	PIP PGR MUC1 KRT5 ESR2 ESR1
18	breast cancer	27.8	PRLR PIP PGR MUC1 KRT5 HSP90AA1
19	nonmucinous bronchioloalveolar adenocarcinoma	10.4	ESR2 ESR1
20	gallbladder signet ring cell adenocarcinoma	10.4	MUC1 CDH1
21	vulvar intraepithelial neoplasia	10.4	CTNNB1 CDH1
22	bile duct cystadenoma	10.4	ESR2 ESR1
23	postmenopausal atrophic vaginitis	10.4	ESR2 ESR1
24	goblet cell carcinoid	10.4	CTNNB1 CDH1
25	bartholin's gland adenoma	10.4	PGR ESR1
26	bartholin's gland adenoid cystic carcinoma	10.4	PGR ESR1
27	uterine corpus adenosarcoma	10.4	PGR ESR1
28	bartholin's gland benign neoplasm	10.4	PGR ESR1
29	vestibular gland benign neoplasm	10.4	PGR ESR1
30	granulomatous endometritis	10.4	PGR ESR1
31	lung leiomyoma	10.4	PGR ESR1
32	liver adenomatosis	10.4	PGR CTNNB1
33	adult type testicular granulosa cell tumor	10.4	PGR ESR1
34	cervical clear cell adenocarcinoma	10.4	PGR ESR1
35	ovarian seromucinous carcinoma	10.3	PGR ESR1
36	endometrial mucinous adenocarcinoma	10.3	PGR MUC1
37	liver leiomyoma	10.3	PGR ESR1
38	pseudomyxoma peritonei	10.3	MUC1 CTNNB1 CDH1
39	euryblepharon	10.3	CTNND1 CDH1
40	intravascular fasciitis	10.3	ESR1 CTNNB1
41	submandibular gland cancer	10.3	HSP90AA1 ERBB2
42	intravenous leiomyomatosis	10.3	PGR ESR1
43	apocrine adenosis of breast	10.3	PGR ERBB2
44	intracranial meningioma	10.3	PGR ESR1
45	chronic tympanitis	10.3	PGR MUC1 ESR1
46	gender identity disorder	10.3	PGR ESR2 ESR1
47	progesterone resistance	10.3	PGR ESR2 ESR1
48	vaginal cancer	10.3	PGR ESR2 ESR1
49	estrogen excess	10.3	PGR ESR2 ESR1
50	vulvar leiomyoma	10.3	PGR ESR1

Graphical network of the top 20 diseases related to Lobular Neoplasia:

Sources

Symptoms & Phenotypes for Lobular Neoplasia

GenomeRNAi Phenotypes related to Lobular Neoplasia according to GeneCards Suite gene sharing:

²⁶

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased cell migration	GR00055-A-1	8.65	CASK
2	Increased focal adhesion (FA) area, decreased number of small and round FAs, increased peripheral FA formation, increased cell spreading	GR00210-A	8.32	CTNNB1

MGI Mouse Phenotypes related to Lobular Neoplasia:

⁴⁶ (show all 11)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	10.37	BRCA1 BRCA2 CASK CD2BP2 CDH1 CTNNA1
2	endocrine/exocrine gland	MP:0005379	10.25	BRCA1 BRCA2 CDH1 CTNNA1 CTNNB1 CTNND1
3	digestive/alimentary	MP:0005381	10.22	BRCA1 BRCA2 CASK CDH1 CTNNB1 CTNND1
4	growth/size/body region	MP:0005378	10.22	BRCA1 BRCA2 CASK CD2BP2 CDH1 CTNNA1
5	integument	MP:0010771	10.18	BRCA1 BRCA2 CASK CDH1 CTNNA1 CTNNB1
6	embryo	MP:0005380	10.16	BRCA1 BRCA2 CD2BP2 CDH1 CTNNA1 CTNNB1
7	mortality/aging	MP:0010768	10.1	BRCA1 BRCA2 CASK CD2BP2 CDH1 CTNNA1
8	limbs/digits/tail	MP:0005371	10.06	BRCA1 BRCA2 CASK CTNNA1 CTNNB1 ERBB2
9	neoplasm	MP:0002006	9.9	BRCA1 BRCA2 CDH1 CTNNA1 CTNNB1 CTNND1
10	reproductive system	MP:0005389	9.73	BRCA1 BRCA2 CASK CDH1 CTNNB1 ERBB2
11	skeleton	MP:0005390	9.36	BRCA1 BRCA2 CASK CTNNA1 CTNNB1 ERBB2

Sources

Drugs & Therapeutics for Lobular Neoplasia

Drugs for Lobular Neoplasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 30)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Tamoxifen

Approved

Phase 2, Phase 3

10540-29-1

2733526

Afimoxifene

Investigational

Phase 2, Phase 3

68392-35-8

Hydroxytamoxifen

Phase 2, Phase 3

Hormones

Phase 2, Phase 3

Estrogen Antagonists

Phase 2, Phase 3

Estrogen Receptor Antagonists

Phase 2, Phase 3

Hormone Antagonists

Phase 2, Phase 3

Antineoplastic Agents, Hormonal

Phase 2, Phase 3

Estrogens

Phase 2, Phase 3

Estrogen Receptor Modulators

Phase 2, Phase 3

Epirubicin

Approved

Phase 2

56420-45-2

41867

Vinorelbine

Approved, Investigational

Phase 2

71486-22-1

60780 44424639

Trastuzumab

Approved, Investigational

Phase 2

180288-69-1

9903

Docetaxel

Approved, Investigational

Phase 2

114977-28-5

148124

Capecitabine

Approved, Investigational

Phase 2

154361-50-9

60953

Bevacizumab

Approved, Investigational

Phase 2

216974-75-3

Cyclophosphamide

Approved, Investigational

Phase 2

50-18-0, 6055-19-2

2907

Tubulin Modulators

Phase 2

Antirheumatic Agents

Phase 2

Antineoplastic Agents, Immunological

Phase 2

Immunosuppressive Agents

Phase 2

Angiogenesis Inhibitors

Phase 2

Antimitotic Agents

Phase 2

Antibiotics, Antitubercular

Phase 2

Alkylating Agents

Phase 2

Anti-Bacterial Agents

Phase 2

Immunologic Factors

Phase 2

Antimetabolites

Phase 2

Iodine

Approved, Investigational

7553-56-2

807

Zinc

Approved, Investigational

7440-66-6

32051

Interventional clinical trials:

#	Name	Status	NCT ID	Phase	Drugs
1	A Phase IIB Randomized Trial of Oral Tamoxifen vs. Topical 4-hydroxytamoxifen Gel vs. Control in Women With Atypical Hyperplasia or Lobular Carcinoma In Situ	Not yet recruiting	NCT04570956	Phase 2, Phase 3	Tamoxifen;Topical 4-OHT( 4-hydroxytamoxifen)gel 2 mg/each breast/day;Placebo
2	"Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer"	Unknown status	NCT01641406	Phase 2	Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab;Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab;Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab
3	GLACIER: A Study to Investigate the Genetics of LobulAr Carcinoma In Situ in EuRope	Unknown status	NCT00536718
4	Management of Ductal Carcinoma in Situ (DCIS) or Pure Micro-invasive (DCIS-MI) Extended Breast, Axillary Node Sentinel Site (GAS) When the Diagnosis is Made by Biopsy and Treatment by Mastectomy Immediately. Descriptive Study	Completed	NCT01841749
5	Evaluation of a Small Field of View Gamma Camera for Scintimammography in Patients With Atypical Ductal Hyperplasia, Atypical Lobular Hyperplasia, and Lobular Carcinoma In Situ	Completed	NCT00620087
6	The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma, DCIS, or Atypical Ductal Hyperplasia (ADH) in Patients Diagnosed With Lobular Neoplasia of the Breast by Core Needle Biopsy	Completed	NCT00146536
7	Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women With Atypical Hyperplasia or Lobular Carcinoma In Situ - Making Informed Choices on Incorporating Chemoprevention Into Care (MiChoice)	Recruiting	NCT04496739
8	Molecular Genetic Basis of Invasive Breast Cancer Risk Associated With Lobular Carcinoma in Situ	Active, not recruiting	NCT00581750

Search NIH Clinical Center for Lobular Neoplasia

Sources

Genetic Tests for Lobular Neoplasia

Sources

Anatomical Context for Lobular Neoplasia

MalaCards organs/tissues related to Lobular Neoplasia:

⁴⁰

Breast, Ovary, Lung, Lymph Node, Colon, Skin, Prostate

Sources

Publications for Lobular Neoplasia

Articles related to Lobular Neoplasia:

(show top 50) (show all 1160)

#	Title	Authors	PMID	Year
1	Assessing Risk of Breast Cancer: A Review of Risk Prediction Models. ⁶¹	Kim G...Bahl M	33778488	2021
2	Breast cancer detection by dedicated breast positron emission tomography according to the World Health Organization classification of breast tumors. ⁶¹	Sasada S...Okada M	33685728	2021
3	Identification of a localization wire tip in an occult breast lesion using a handheld magnetometer. ⁶¹	Szynglarewicz B...Matkowski R	33754504	2021
4	The lobular neoplasia enigma: management and prognosis in a long follow-up case series. ⁶¹	Metovic J...Castellano I	33736652	2021
5	Upgrade at excisional biopsy after a core needle biopsy diagnosis of classic lobular carcinoma in situ. ⁶¹	Pride RM...Hieken TJ	32861439	2021
6	High-Risk Lesions Detected by MRI-Guided Core Biopsy: Upgrade Rates at Surgical Excision and Implications for Management. ⁶¹	Michaels AY...Abbey GN	33439046	2021
7	Contrast-Enhanced Digital Mammography Screening for Intermediate-Risk Women With a History of Lobular Neoplasia. ⁶¹	Hogan MP...Jochelson MS	33787291	2021
8	Positive predictive value for malignancy of uncertain malignant potential (B3) breast lesions diagnosed on vacuum-assisted biopsy (VAB): is surgical excision still recommended? ⁶¹	Lucioni M...Di Giulio G	32816199	2021
9	Implementation of a High-Risk Breast Clinic for Comprehensive Care of Women With Elevated Breast Cancer Risk Identified by Risk Assessment Models in the Community. ⁶¹	Laws A...Mulvey TM	32822256	2021
10	Management of high-risk breast lesions diagnosed on core biopsies and experiences from prospective high-risk breast lesion conferences at an academic institution. ⁶¹	Li X...Cohen MA	33068196	2021
11	Impact of lobular carcinoma in situ on local recurrence in breast cancer treated with breast conservation therapy: a systematic review and meta-analysis. ⁶¹	Harris CG...Eslick GD	33634956	2021
12	Longitudinal study of breast cancer risk markers. ⁶¹	Zarwan C...Pories SE	33099843	2021
13	Lobular carcinoma in situ: diagnostic criteria and molecular correlates. ⁶¹	Sokolova A...Lakhani SR	33024303	2021
14	Ductal and lobular carcinoma in situ arising within an enlarging biopsy proven fibroadenoma. ⁶¹	Feliciano YZ...Yepes M	33468635	2021
15	[Overall survival and survival without local recurrence in case of radiotherapy of the tumor bed of ductal carcinomas in situ of the breast: Review of the literature]. ⁶¹	Kuntz L...Antoni D	33401020	2021
16	Classical Lobular Carcinoma In Situ Arising From an Intraductal Papilloma of the Breast: A Case Report. ⁶¹	Kim NI...Lee JS	33403884	2021
17	Performance of a clinical and imaging-based multivariate model as decision support tool to help save unnecessary surgeries for high-risk breast lesions. ⁶¹	Polat DS...Dogan BE	33010022	2021
18	[A Case of Lobular Carcinoma In Situ Occurring in a Fibroadenoma of the Breast]. ⁶¹	Ueno S...Honma M	33468741	2021
19	Lobular intraepithelial neoplasia: Outcomes and optimal management. ⁶¹	Boland PA...Walsh SM	33270304	2020
20	Lobular neoplasia occult on conventional imaging and diagnosed on MRI-guided biopsy: can we estimate upgrade on surgical pathology? ⁶¹	Amitai Y...Freitas V	32888139	2020
21	B3 lesion upgrade rates in a tertiary Australian breast centre: a 8-year experience (2012-2019). ⁶¹	Huang YY...Ponniah AK	32969161	2020
22	Descriptive study comparing outcomes of classic and nonclassic lobular carcinoma in situ (florid and pleomorphic) initially diagnosed on core needle biopsy. ⁶¹	Singh K...Quddus MR	33047861	2020
23	Clinical outcomes of patients with ductal carcinoma in situ in Hong Kong: 10-year territory-wide cancer registry study. ⁶¹	Co M...Kwong A	33277445	2020
24	E-cadherin to P-cadherin switching in lobular breast cancer with tubular elements. ⁶¹	Christgen M...Kreipe H	32572153	2020
25	Preneoplasia of the Breast and Molecular Landscape. ⁶¹	Alvarado-Cabrero I...Estevez-Castro R	32972772	2020
26	Dynamic Changes of Convolutional Neural Network-based Mammographic Breast Cancer Risk Score Among Women Undergoing Chemoprevention Treatment. ⁶¹	Manley H...Ha R	33277192	2020
27	Do Histopathology and Clinical Outcomes of Breast Atypia Vary by Race/Ethnicity? ⁶¹	Sergesketter AR...Plichta JK	32563761	2020
28	Improving contrast and spatial resolution in crystal analyzer-based x-ray dark-field imaging: Theoretical considerations and experimental demonstration. ⁶¹	Ando M...Gupta R	32770681	2020
29	Baseline Screening MRI Uptake and Findings in Women with ≥ 20% Lifetime Risk of Breast Cancer. ⁶¹	Laws A...Coopey SB	32683633	2020
30	Benign breast papillomas without atypia diagnosed with core needle biopsy: Outcome of surgical excision and imaging follow-up. ⁶¹	Polat DS...Goudreau SH	32905954	2020
31	Risk for Upgrade to Malignancy After Breast Core Needle Biopsy Diagnosis of Lobular Neoplasia: A Systematic Review and Meta-Analysis. ⁶¹	Shehata MN...Lowry KP	32861602	2020
32	Pleomorphic lobular carcinoma in situ composed of signet ring cells mimicking cribriform ductal carcinoma in situ. ⁶¹	Kavesh M...Asirvatham JR	32588511	2020
33	Role of vacuum assisted excision in minimising overtreatment of ductal atypias. ⁶¹	McMahon MA...Sharma N	32919262	2020
34	Use of bilateral prophylactic nipple-sparing mastectomy in patients with high risk of breast cancer. ⁶¹	Valero MG...Sacchini V	32432359	2020
35	Clinicopathologic update of calcium oxalate in breast: A 15-year retrospective review. ⁶¹	Haghayeghi K...Wang Y	32564487	2020
36	Lesions of uncertain malignant potential of the breast (B3) on vacuum-assisted biopsy for microcalcifications: Predictors of malignancy. ⁶¹	Mariscotti G...Houssami N	32795765	2020
37	Disparities in Risk Reduction Therapy Recommendations for Young Women With Lobular Carcinoma In-Situ. ⁶¹	Bandera BC...Goldfarb M	32081572	2020
38	Apocrine Variant of Pleomorphic Lobular Carcinoma In Situ: Further Clinical, Histopathologic, Immunohistochemical, and Molecular Characterization of an Emerging Entity. ⁶¹	Zhong E...Hoda SA	32317606	2020
39	Invasive plasmacytoid urothelial carcinoma: A comparative study of E-cadherin and P120 catenin. ⁶¹	Sangoi AR...Kunju LP	32673685	2020
40	Management of women at increased risk for breast cancer secondary to high-risk proliferative lesions and family history of the disease. ⁶¹	Cen C...Schnabel F	32741042	2020
41	Pathologic Evaluation of Breast Tissue From Transmasculine Individuals Undergoing Gender-Affirming Chest Masculinization. ⁶¹	Hernandez A...Darvishian F	31816268	2020
42	Genomic profiling of pleomorphic and florid lobular carcinoma in situ reveals highly recurrent ERBB2 and ERRB3 alterations. ⁶¹	Harrison BT...King TA	31932682	2020
43	[Histological lesions of risk of breast carcinoma. Survival guide for the general pathologist]. ⁶¹	Marco Molina V...Garcia Hernandez F	32650967	2020
44	Do Body Mass Index and Breast Density Impact Cancer Risk Among Women with Lobular Carcinoma In Situ? ⁶¹	Minami CA...Pilewskie ML	31898097	2020
45	Carcinoma In Situ Involving Sclerosing Adenosis on Core Biopsy: Diagnostic Pearls to Aid the Practicing Clinician and Avoid Overtreatment. ⁶¹	Richards D...Middleton LP	32700071	2020
46	ASO Author Reflections: Conceptualizing Risk in Women with Lobular Carcinoma In Situ. ⁶¹	Minami C...Pilewskie ML	32246310	2020
47	Inter-observer reproducibility of classical lobular neoplasia (B3 lesions) in preoperative breast biopsies: a study of the Swiss Working Group of breast and gynecopathologists. ⁶¹	Moskovszky L...Varga Z	32232656	2020
48	Genetic analysis of pleomorphic and florid lobular carcinoma in situ variants: frequent ERBB2/ERBB3 alterations and clonal relationship to classic lobular carcinoma in situ and invasive lobular carcinoma. ⁶¹	Shamir ER...Krings G	31907376	2020
49	Three-year Trends in Diagnosis of B3 Breast Lesions and Their Upgrade Rates to Malignant Lesions. ⁶¹	Griffiths R...Szollosi Z	32171702	2020
50	Non-invasive lobular neoplasia of the breast: Morphologic features, clinical presentation, and management dilemmas. ⁶¹	Calle C...Brogi E	32500575	2020

Sources

Genes for Lobular Neoplasia

Genes related to Lobular Neoplasia (0 elite genes):

(show all 21)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	CDH1	Cadherin 1	Protein Coding	14.9	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
2	ESR1	Estrogen Receptor 1	Protein Coding	14.04	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
3	ESR2	Estrogen Receptor 2	Protein Coding	12.09	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
4	CTNNB1	Catenin Beta 1	Protein Coding	12.09	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
5	MUC1	Mucin 1, Cell Surface Associated	Protein Coding	11.77	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	PRLR	Prolactin Receptor	Protein Coding	11.76	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	CTNNA1	Catenin Alpha 1	Protein Coding	11.72	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
8	MIR375	MicroRNA 375	RNA Gene	11.29	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	HSP90AA1	Heat Shock Protein 90 Alpha Family Class A Member 1	Protein Coding	11.18	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	CT45A10	Cancer/Testis Antigen Family 45 Member A10	Protein Coding	8.1	DISEASES inferred ¹⁵ ¹⁵
11	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	7.53	DISEASES inferred ¹⁵
12	PGR	Progesterone Receptor	Protein Coding	7.47	DISEASES inferred ¹⁵
13	BRCA1	BRCA1 DNA Repair Associated	Protein Coding	7.41	DISEASES inferred ¹⁵
14	CD2BP2	CD2 Cytoplasmic Tail Binding Protein 2	Protein Coding	7.23	DISEASES inferred ¹⁵
15	BRCA2	BRCA2 DNA Repair Associated	Protein Coding	7.21	DISEASES inferred ¹⁵
16	CASK	Calcium/Calmodulin Dependent Serine Protein Kinase	Protein Coding	6.93	DISEASES inferred ¹⁵
17	CTNND1	Catenin Delta 1	Protein Coding	6.48	DISEASES inferred ¹⁵
18	CCL27	C-C Motif Chemokine Ligand 27	Protein Coding	6.46	DISEASES inferred ¹⁵
19	PIP	Prolactin Induced Protein	Protein Coding	6.27	DISEASES inferred ¹⁵
20	KRT5	Keratin 5	Protein Coding	6.24	DISEASES inferred ¹⁵
21	TP53	Tumor Protein P53	Protein Coding	6.17	DISEASES inferred ¹⁵

Sources

Variations for Lobular Neoplasia

Cosmic variations for Lobular Neoplasia:

⁹ (show top 50) (show all 3541)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location	Conf
1	COSM88264551	ZRSR2	breast,NS,carcinoma,lobular carcinoma	c.772-1G>C	p.?	23:15818586-15818586	6
2	COSM87279654	ZFHX3	breast,NS,carcinoma,lobular carcinoma	c.4556C>G	p.S1519*	16:72798126-72798126	6
3	COSM149285883	ZFHX3	breast,NS,carcinoma,lobular carcinoma	c.4556C>G	p.S1519*	16:72798126-72798126	6
4	COSM149315898	ZFHX3	breast,NS,carcinoma,lobular carcinoma	c.7262C>G	p.S2421*	16:72795420-72795420	6
5	COSM102029000	ZFHX3	breast,NS,carcinoma,lobular carcinoma	c.1814C>G	p.S605*	16:72798126-72798126	6
6	COSM102040958	ZFHX3	breast,NS,carcinoma,lobular carcinoma	c.4520C>G	p.S1507*	16:72795420-72795420	6
7	COSM102023834	ZFHX3	breast,NS,carcinoma,lobular carcinoma	c.6478C>T	p.Q2160*	16:72793462-72793462	6
8	COSM149270832	ZFHX3	breast,NS,carcinoma,lobular carcinoma	c.9220C>T	p.Q3074*	16:72793462-72793462	6
9	COSM87290679	ZFHX3	breast,NS,carcinoma,lobular carcinoma	c.7262C>G	p.S2421*	16:72795420-72795420	6
10	COSM87274898	ZFHX3	breast,NS,carcinoma,lobular carcinoma	c.9220C>T	p.Q3074*	16:72793462-72793462	6
11	COSM136835751	YES1	breast,NS,carcinoma,lobular carcinoma	c.1105G>C	p.D369H	18:739782-739782	6
12	COSM152021957	YES1	breast,NS,carcinoma,lobular carcinoma	c.1090G>C	p.D364H	18:739782-739782	6
13	COSM89893843	YES1	breast,NS,carcinoma,lobular carcinoma	c.1090G>C	p.D364H	18:739782-739782	6
14	COSM133268543	YAP1	breast,NS,carcinoma,lobular carcinoma	c.1078C>T	p.Q360*	11:102223703-102223703	6
15	COSM145023934	YAP1	breast,NS,carcinoma,lobular carcinoma	c.964C>T	p.Q322*	11:102223703-102223703	6
16	COSM128447630	YAP1	breast,NS,carcinoma,lobular carcinoma	c.952C>T	p.Q318*	11:102223703-102223703	6
17	COSM127994003	YAP1	breast,NS,carcinoma,lobular carcinoma	c.1066C>T	p.Q356*	11:102223703-102223703	6
18	COSM126968980	YAP1	breast,NS,carcinoma,lobular carcinoma	c.580C>T	p.Q194*	11:102223703-102223703	6
19	COSM85232645	YAP1	breast,NS,carcinoma,lobular carcinoma	c.1114C>T	p.Q372*	11:102223703-102223703	6
20	COSM143037036	YAP1	breast,NS,carcinoma,lobular carcinoma	c.1126C>T	p.Q376*	11:102223703-102223703	6
21	COSM90943480	YAP1	breast,NS,carcinoma,lobular carcinoma	c.1012C>T	p.Q338*	11:102223703-102223703	6
22	COSM101979646	XPO1	breast,NS,carcinoma,lobular carcinoma	c.1160C>G	p.S387C	2:61493979-61493979	6
23	COSM104239359	XPO1	breast,NS,carcinoma,lobular carcinoma	c.1160C>G	p.S387C	2:61493979-61493979	6
24	COSM104241154	XPO1	breast,NS,carcinoma,lobular carcinoma	c.2260G>T	p.E754*	2:61488218-61488218	6
25	COSM104886058	XPO1	breast,NS,carcinoma,lobular carcinoma	c.1160C>G	p.S387C	2:61493979-61493979	6
26	COSM101981526	XPO1	breast,NS,carcinoma,lobular carcinoma	c.2260G>T	p.E754*	2:61488218-61488218	6
27	COSM104888500	XPO1	breast,NS,carcinoma,lobular carcinoma	c.2260G>T	p.E754*	2:61488218-61488218	6
28	COSM108081568	XIAP	breast,NS,carcinoma,lobular carcinoma	c.1240C>G	p.L414V	23:123900633-123900633	6
29	COSM92178574	XIAP	breast,NS,carcinoma,lobular carcinoma	c.1240C>G	p.L414V	23:123900633-123900633	6
30	COSM94288275	XIAP	breast,NS,carcinoma,lobular carcinoma	c.1240C>G	p.L414V	23:123900633-123900633	6
31	COSM90876009	WNK1	breast,NS,carcinoma,lobular carcinoma	c.6569C>G	p.S2190C	12:900596-900596	6
32	COSM130224650	WNK1	breast,NS,carcinoma,lobular carcinoma	c.7349C>G	p.S2450C	12:900596-900596	6
33	COSM128151609	WNK1	breast,NS,carcinoma,lobular carcinoma	c.7808C>G	p.S2603C	12:900596-900596	6
34	COSM132334333	WNK1	breast,NS,carcinoma,lobular carcinoma	c.1255G>C	p.E419Q	12:830104-830104	6
35	COSM132334343	WNK1	breast,NS,carcinoma,lobular carcinoma	c.5825C>G	p.S1942C	12:900596-900596	6
36	COSM90876002	WNK1	breast,NS,carcinoma,lobular carcinoma	c.1255G>C	p.E419Q	12:830104-830104	6
37	COSM130224638	WNK1	breast,NS,carcinoma,lobular carcinoma	c.1255G>C	p.E419Q	12:830104-830104	6
38	COSM92011980	WNK1	breast,NS,carcinoma,lobular carcinoma	c.1255G>C	p.E419Q	12:830104-830104	6
39	COSM128151601	WNK1	breast,NS,carcinoma,lobular carcinoma	c.1255G>C	p.E419Q	12:830104-830104	6
40	COSM92011987	WNK1	breast,NS,carcinoma,lobular carcinoma	c.7325C>G	p.S2442C	12:900596-900596	6
41	COSM88292485	VHL	breast,NS,carcinoma,lobular carcinoma	c.241C>T	p.P81S	3:10142088-10142088	6
42	COSM90665450	VHL	breast,NS,carcinoma,lobular carcinoma	c.439C>G	p.L147V	3:10149885-10149885	6
43	COSM90653017	VHL	breast,NS,carcinoma,lobular carcinoma	c.241C>T	p.P81S	3:10142088-10142088	6
44	COSM88303015	VHL	breast,NS,carcinoma,lobular carcinoma	c.562C>G	p.L188V	3:10149885-10149885	6
45	COSM133858401	USP28	breast,NS,carcinoma,lobular carcinoma	c.1675G>A	p.D559N	11:113809177-113809177	6
46	COSM83992324	USP28	breast,NS,carcinoma,lobular carcinoma	c.2050G>A	p.D684N	11:113809177-113809177	6
47	COSM132241970	USP28	breast,NS,carcinoma,lobular carcinoma	c.1174G>A	p.D392N	11:113809177-113809177	6
48	COSM140659623	TTN	breast,NS,carcinoma,lobular carcinoma	c.97193-1G>C	p.?	2:178542564-178542564	6
49	COSM96773374	TTN	breast,NS,carcinoma,lobular carcinoma	c.10945G>A	p.E3649K	2:178741574-178741574	6
50	COSM139462905	TTN	breast,NS,carcinoma,lobular carcinoma	c.40301G>A	p.R13434K	2:178621600-178621600	6

Sources

Expression for Lobular Neoplasia

Search GEO for disease gene expression data for Lobular Neoplasia.

Sources

Pathways for Lobular Neoplasia

Pathways related to Lobular Neoplasia according to GeneCards Suite gene sharing:

(show all 33)

#	Super pathways	Score	Top Affiliating Genes
1	ERK Signaling ⁶³ Show member pathways ILK Signaling ⁶³ MAPK Signaling ⁶³ Molecular Mechanisms of Cancer ⁶³ Rho Family GTPases ⁶³	13.72	PIP MUC1 ESR2 ESR1 ERBB2 CTNND1
2	PAK Pathway ⁶³ Show member pathways Antioxidant Action of Vitamin-C ⁶³ Epithelial Adherens Junctions ⁶³	13.25	PIP ERBB2 CTNND1 CTNNB1 CTNNA1 CDH1
3	Endometrial cancer ³⁶ Show member pathways Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁵ Chronic myeloid leukemia ³⁶ Colorectal cancer ³⁶ Pancreatic cancer ³⁶ Prostate cancer ³⁶ Signal transduction PTEN pathway ²³ Thyroid cancer ³⁶	12.73	HSP90AA1 ERBB2 CTNNB1 CTNNA1 CDH1 BRCA2
4	Development HGF signaling pathway ²³ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²³ Apoptosis and survival NGF signaling pathway ²³ Apoptosis and survival Role of CDK5 in neuronal death and survival ²³ Development Neurotrophin family signaling ²³ MET activates STAT3 ⁶⁵ Neurotrophin signaling pathway ³⁶ Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) ¹ Signaling of Hepatocyte Growth Factor Receptor ¹	12.66	ESR1 ERBB2 CTNNB1 CTNNA1 CDH1
5	Cell junction organization ⁶⁵ Show member pathways Adherens junctions interactions ⁶⁵ Cell-Cell communication ⁶⁵ Cell-cell junction organization ⁶⁵ Cell-extracellular matrix interactions ⁶⁵ DSCAM interactions ⁶⁵ Localization of the PINCH-ILK-PARVIN complex to focal adhesions ⁶⁵ Nectin/Necl trans heterodimerization ⁶⁵ Regulation of cytoskeletal remodeling and cell spreading by IPP complex components ⁶⁵ Signal regulatory protein (SIRP) family interactions ⁶⁵ Tight junction interactions ⁶⁵ Type I hemidesmosome assembly ⁶⁵	12.65	CTNND1 CTNNB1 CTNNA1 CDH1 CASK
6	Glioma ³⁶ Show member pathways Endocrine resistance ³⁶ Melanoma ³⁶ Non-small cell lung cancer ³⁶ Signaling Pathways in Glioblastoma ¹	12.6	ESR2 ESR1 ERBB2 CDH1 BRCA2 BRCA1
7	Pathways in cancer ³⁶	12.48	HSP90AA1 ESR2 ESR1 ERBB2 CTNNB1 CTNNA1
8	Prolactin Signaling Pathway ¹ ³⁶ Show member pathways Development Prolactin receptor signaling ²³ Leptin signaling pathway ¹	12.41	PRLR ESR2 ESR1 ERBB2
9	Development VEGF signaling via VEGFR2 - generic cascades ²³ Show member pathways Development VEGF signaling and activation ²³ VEGF - VEGF R2 Signaling Pathways ⁶⁴	12.33	HSP90AA1 ESR1 CTNNB1 BRCA1
10	Development EGFR signaling pathway ²³ Show member pathways Development ERBB-family signaling ²³ EGF Pathway ⁶³ ErbB receptor signaling network ¹	12.23	MUC1 HSP90AA1 ERBB2 CTNNB1 CDH1
11	CD28 co-stimulation ⁶⁵ Show member pathways Activation of AKT2 ⁶⁵ CD28 dependent PI3K/Akt signaling ⁶⁵ CD28 dependent Vav1 pathway ⁶⁵ Costimulation by the CD28 family ⁶⁵ VEGFR2 mediated vascular permeability ⁶⁵	12.16	HSP90AA1 CTNND1 CTNNB1 CTNNA1
12	Estrogen signaling pathway (KEGG) ³⁶	12.04	PGR HSP90AA1 ESR2 ESR1
13	Integrated Breast Cancer Pathway ¹	12.04	ESR1 CTNNB1 CDH1 BRCA2 BRCA1
14	Remodeling of Adherens Junctions ⁶³	12.03	CTNND1 CTNNB1 CTNNA1 CDH1
15	Gastric cancer ³⁶ Show member pathways Breast cancer ³⁶ Hepatocellular carcinoma ³⁶	11.94	PGR ESR2 ESR1 ERBB2 CTNNB1 CTNNA1
16	Signaling by ERBB4 ⁶⁵ Show member pathways Downregulation of ERBB4 signaling ⁶⁵ ErbB4 signaling events ¹ Nuclear signaling by ERBB4 ⁶⁵	11.9	PRLR PGR ESR1 ERBB2
17	Adhesion ⁴	11.89	MUC1 CTNND1 CTNNB1 CTNNA1 CDH1
18	Listeria monocytogenes entry into host cells ⁶⁵ Show member pathways E-cadherin signaling events ¹ EGFR downregulation ⁶⁵ InlA-mediated entry of Listeria monocytogenes into host cells ⁶⁵ InlB-mediated entry of Listeria monocytogenes into host cell ⁶⁵ Negative regulation of MET activity ⁶⁵	11.79	CTNND1 CTNNB1 CDH1
19	Nuclear Receptor transcription pathway ⁶⁵ Show member pathways Nuclear Receptors ¹	11.78	PGR ESR2 ESR1
20	Bacterial invasion of epithelial cells ³⁶	11.7	CTNNB1 CTNNA1 CDH1
21	Cell adhesion_Endothelial cell contacts by non-junctional mechanisms ²³	11.38	CTNND1 CTNNB1 CTNNA1
22	Arf6 trafficking events ¹	11.38	CTNND1 CTNNB1 CTNNA1 CDH1
23	N-cadherin signaling events ¹	11.29	CTNND1 CTNNB1 CTNNA1
24	Ovarian Infertility Genes ¹	11.27	PRLR PGR ESR2
25	Stabilization and expansion of the E-cadherin adherens junction ¹	11.27	CTNND1 CTNNB1 CTNNA1 CDH1
26	Cell adhesion_Endothelial cell contacts by junctional mechanisms ²³	11.26	CTNND1 CTNNB1 CTNNA1
27	Cell adhesion_Cadherin-mediated cell adhesion ²³	11.22	CTNND1 CTNNB1 CTNNA1 CDH1
28	Adherens junction ³⁶	11.2	ERBB2 CTNND1 CTNNB1 CTNNA1 CDH1
29	Nectin adhesion pathway ¹	11.12	CTNNB1 CTNNA1 CDH1
30	E-cadherin signaling in the nascent adherens junction ¹	11.08	CTNND1 CTNNB1 CTNNA1 CDH1
31	E-cadherin signaling in keratinocytes ¹	10.99	CTNND1 CTNNA1 CDH1
32	RHO GTPases activate IQGAPs ⁶⁵	10.78	CTNNB1 CTNNA1 CDH1
33	Aromatase Inhibitor Pathway (Breast Cell), Pharmacodynamics ⁶⁰	10.21	ESR2 ESR1

Sources

GO Terms for Lobular Neoplasia

Cellular components related to Lobular Neoplasia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	cytoplasm	GO:0005737	10.32	PGR MUC1 KRT5 HSP90AA1 ESR1 ERBB2
2	nucleus	GO:0005634	10.3	PIP PGR MUC1 KRT5 HSP90AA1 ESR2
3	cell-cell junction	GO:0005911	9.62	CTNND1 CTNNB1 CTNNA1 CASK
4	Schaffer collateral - CA1 synapse	GO:0098685	9.58	CTNND1 CTNNB1 CASK
5	lamellipodium	GO:0030027	9.56	CTNND1 CTNNB1 CTNNA1 CDH1
6	adherens junction	GO:0005912	9.46	CTNND1 CTNNB1 CTNNA1 CDH1
7	presynaptic active zone cytoplasmic component	GO:0098831	9.43	CTNND1 CTNNB1
8	zonula adherens	GO:0005915	9.37	CTNND1 CTNNA1
9	flotillin complex	GO:0016600	9.13	CTNNB1 CTNNA1 CDH1
10	catenin complex	GO:0016342	8.92	CTNND1 CTNNB1 CTNNA1 CDH1

Biological processes related to Lobular Neoplasia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of transcription, DNA-templated	GO:0045893	9.91	ESR2 ESR1 CTNNB1 CDH1 BRCA2 BRCA1
2	regulation of apoptotic process	GO:0042981	9.78	HSP90AA1 ESR1 CTNNB1 BRCA1
3	cell-cell adhesion	GO:0098609	9.71	CTNND1 CTNNB1 CTNNA1 CDH1
4	response to estrogen	GO:0043627	9.63	ESR1 CTNNA1 BRCA1
5	DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	GO:0006978	9.5	MUC1 BRCA2 BRCA1
6	adherens junction organization	GO:0034332	9.46	CTNND1 CTNNB1 CTNNA1 CDH1
7	intracellular steroid hormone receptor signaling pathway	GO:0030518	9.43	PGR ESR2 ESR1
8	chordate embryonic development	GO:0043009	9.37	BRCA2 BRCA1
9	entry of bacterium into host cell	GO:0035635	9.13	CTNND1 CTNNB1 CDH1
10	cellular response to indole-3-methanol	GO:0071681	8.92	CTNNB1 CTNNA1 CDH1 BRCA1

Molecular functions related to Lobular Neoplasia according to GeneCards Suite gene sharing:

(show all 11)

#	Name	GO ID	Score	Top Affiliating Genes
1	protein binding	GO:0005515	10.45	PRLR PIP PGR MUC1 KRT5 HSP90AA1
2	enzyme binding	GO:0019899	9.83	PGR ESR2 ESR1 CTNNB1 BRCA1
3	nuclear receptor activity	GO:0004879	9.58	PGR ESR2 ESR1
4	gamma-catenin binding	GO:0045295	9.49	CTNNA1 CDH1
5	nitric-oxide synthase regulator activity	GO:0030235	9.46	HSP90AA1 ESR1
6	steroid binding	GO:0005496	9.43	PGR ESR2 ESR1
7	estrogen receptor activity	GO:0030284	9.37	ESR2 ESR1
8	identical protein binding	GO:0042802	9.36	PIP PGR HSP90AA1 ESR2 ESR1 ERBB2
9	steroid hormone receptor activity	GO:0003707	9.33	PGR ESR2 ESR1
10	estrogen response element binding	GO:0034056	9.32	ESR2 ESR1
11	beta-catenin binding	GO:0008013	9.26	ESR1 CTNNB1 CTNNA1 CDH1

Sources

Sources for Lobular Neoplasia

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GARD

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MedlinePlus Genetics

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM via Orphanet

⁵⁷ OMIM® (Updated 20-May-2021)

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ Tocris

⁷⁰ UMLS

⁷¹ UMLS via Orphanet

⁷² UniProtKB/Swiss-Prot

⁷³ Wikipedia